Georg Maschmeyer

Georg Maschmeyer

Auto-generated profile, based on publicly available information

Georg Maschmeyer

German Society of Hematology and Medical Oncology (DGHO) and Charité University Medicine Berlin, Campus Benjamin Franklin; Department of Hematology, Oncology and Tumor, Charité University Medicine Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Drugs
Verified
Journal Article
Closed access
PDF file
GMGeorg Maschmeyer
Georg Maschmeyer
AHAntje Haas
Antje Haas
OCOliver A. Cornely
Oliver A. Cornely

30 January 2019 in Leukemia
Verified
Journal Article
Open access
PDF file
O(On Behalf Of The European Conference On Infections In Leukemia (Ecil)
On Behalf Of The European Conference On Infections In Leukemia (Ecil)
GMGeorg Maschmeyer
Georg Maschmeyer
JGJulien De Greef
Julien De Greef
SMSibylle C. Mellinghoff
Sibylle C. Mellinghoff
ANAnnamaria Nosari
Annamaria Nosari
JMJohan A. Maertens
Johan A. Maertens
A multitude of new agents for the treatment of hematologic malignancies has been introduced over the past decade. Hematologists, infectious disease specialists, stem cell transplant experts, pulmonologists and radiologists have met within the framework of the European Conference on Infections in Leukemia (ECIL) to provide a critical state-of-the-art on infectious complications associated with immunotherapeutic and molecular targeted agents used in clinical routine. For brentuximab vedotin, blinatumomab, CTLA4- and PD-1/PD-L1-inhibitors as well as for ibrutinib, idelalisib, HDAC inhibitors, mTOR inhibitors, ruxolitinib, and venetoclax, a detailed review of data available until August 2018 has been conducted, and specific recommendations for prophylaxis, diagnostic and differential diagnostic procedures as well as for clinical management have been developed.

30 August 2017 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
WHW. J. Heinz
W. J. Heinz
DBDieter Buchheidt
Dieter Buchheidt
MCM. Christopeit
M. Christopeit
MLM. von Lilienfeld-Toal
M. von Lilienfeld-Toal
OCOliver A. Cornely
Oliver A. Cornely
GMG. Maschmeyer
G. Maschmeyer
Fever may be the only clinical symptom at the onset of infection in neutropenic cancer patients undergoing myelosuppressive chemotherapy. A prompt and evidence-based diagnostic and therapeutic approach is mandatory. A systematic search of current literature was conducted, including only full papers and excluding allogeneic hematopoietic stem cell transplant recipients. Recommendations for diagnosis and therapy were developed by an expert panel and approved after plenary discussion by the AGIHO. Randomized clinical trials were mainly available for therapeutic decisions, and new diagnostic procedures have been introduced into clinical practice in the past decade. Stratification into a high-risk versus low-risk patient population is recommended. In high-risk patients, initial empirical antimicrobial therapy should be active against pathogens most commonly involved in microbiologically documented and most threatening infections, including Pseudomonas aeruginosa, but excluding coagulase-negative staphylococci. In patients whose expected duration of neutropenia is more than 7 days and who do not respond to first-line antibacterial treatment, specifically in the absence of mold-active antifungal prophylaxis, further therapy should be directed also against fungi, in particular Aspergillus species. With regard to antimicrobial stewardship, treatment duration after defervescence in persistently neutropenic patients must be critically reconsidered and the choice of anti-infective agents adjusted to local epidemiology. This guideline updates recommendations for diagnosis and empirical therapy of fever of unknown origin in adult neutropenic cancer patients in light of the challenges of antimicrobial stewardship.

15 May 2014 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
GMG. Maschmeyer
G. Maschmeyer
JCJordi Carratala
Jordi Carratala
DBDieter Buchheidt
Dieter Buchheidt
AHAxel Hamprecht
Axel Hamprecht
CHC. P. Heussel
C. P. Heussel
EAE. Azoulay
E. Azoulay
Up to 25% of patients with profound neutropenia lasting for >10 days develop lung infiltrates, which frequently do not respond to broad-spectrum antibacterial therapy. While a causative pathogen remains undetected in the majority of cases, Aspergillus spp., Pneumocystis jirovecii, multi-resistant Gram-negative pathogens, mycobacteria or respiratory viruses may be involved. In at-risk patients who have received trimethoprim–sulfamethoxazole (TMP/SMX) prophylaxis, filamentous fungal pathogens appear to be predominant, yet commonly not proven at the time of treatment initiation. Pathogens isolated from blood cultures, bronchoalveolar lavage (BAL) or respiratory secretions are not always relevant for the etiology of pulmonary infiltrates and should therefore be interpreted critically. Laboratory tests for detecting Aspergillus galactomannan, β-d-glucan or DNA from blood, BAL or tissue samples may facilitate the diagnosis; however, most polymerase chain reaction assays are not yet standardized and validated. Apart from infectious agents, pulmonary side-effects from cytotoxic drugs, radiotherapy or pulmonary involvement by the underlying malignancy should be included into differential diagnosis and eventually be clarified by invasive diagnostic procedures. Pre-emptive treatment with mold-active systemic antifungal agents improves clinical outcome, while other microorganisms are preferably treated only when microbiologically documented. High-dose TMP/SMX is first choice for treatment of Pneumocystis pneumonia, while cytomegalovirus pneumonia is treated primarily with ganciclovir or foscarnet in most patients. In a considerable number of patients, clinical outcome may be favorable despite respiratory failure, so that intensive care should be unrestrictedly provided in patients whose prognosis is not desperate due to other reasons.

13 June 2023 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
JSJannik Stemler
Jannik Stemler
SMSibylle Mellinghoff
Sibylle Mellinghoff
YKYascha Khodamoradi
Yascha Khodamoradi
RSRosanne Sprute
Rosanne Sprute
ACAnnika Y Classen
Annika Y Classen
DTDaniel Teschner
Daniel Teschner
Patients with haematological malignancies (HM) are at high risk of developing invasive fungal disease (IFD) with high morbidity and attributable mortality. We reviewed data published until September 2021 to update the 2017 antifungal prophylaxis recommendations of the German Society of Haematology and Medical Oncology (DGHO). The strong recommendation to administer antifungal prophylaxis in patients with HM with long-lasting neutropenia, i.e. 7 days remains unchanged. Posaconazole remains the drug of choice for mould-active prophylaxis in these patients. Novel treatment options in HM, such as CAR-T-cell treatment or novel targeted therapies for acute myeloid leukaemia (AML) were considered, however, data are insufficient to give general recommendations for routine antifungal prophylaxis in these patients. Major changes regarding specific recommendations compared to the 2017 edition are the now moderate instead of mild support for the recommendations of isavuconazole and voriconazole. Furthermore, published evidence on micafungin allows recommending it at moderate strength for its use in HM. For the first time we included recommendations for non-pharmaceutical measures regarding IFD, comprising the use of high-efficiency particulate air (HEPA) filters, smoking, measures during construction work and neutropenic diets.We reviewed the impact of antifungal prophylaxis with triazoles on drug–drug interactions with novel targeted therapies that are metabolized via cytochrome p450 where triazoles inhibit CYP3A4/5. The working group recommends reducing the dose of venetoclax when used concomitantly with strong CYP3A4 inhibiting antifungals. Furthermore, we reviewed data on the prophylactic use of novel antifungal agents. Currently there is no evidence to support their use in a prophylactic setting in clinical practice.

1 September 2009 in European Journal of Cancer
Verified
Journal Article
Closed access
GMGeorg Maschmeyer
Georg Maschmeyer
TBThomas Beinert
Thomas Beinert
DBDieter Buchheidt
Dieter Buchheidt
OCOliver A. Cornely
Oliver A. Cornely
HEHermann Einsele
Hermann Einsele
GMGloria Mattiuzzi
Gloria Mattiuzzi